Intelligent Bio Solutions starts clinical studies for FDA 510(k) submission to detect codeine via fingerprint

INTELLIGENT BIO SOLUTIONS INC.

Partnered with Cliantha Research for a study in 40 adults to establish codeine detection cut-off levels.
Study uses Intelligent Fingerprinting Drug Screening System with DSR-Plus reader; full data analysis expected by end of March 2026.
Data will support FDA 510(k) submission and planned commercial launch into the multi-billion-dollar U.S. drug screening market.
Company notes over 500,000 tests already sold outside the U.S.; targeting workplace, clinical, and law enforcement segments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.